Your browser doesn't support javascript.
loading
Author Correction: Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry.
Zhang, Hua; Li, Yan; Wang, Hong-Bo; Zhang, Ao; Chen, Mei-Ling; Fang, Zhi-Xin; Dong, Xiao-Dong; Li, Shi-Bing; Du, Yong; Xiong, Dan; He, Jiang-Yi; Li, Man-Zhi; Liu, Yan-Min; Zhou, Ai-Jun; Zhong, Qian; Zeng, Yi-Xin; Kieff, Elliott; Zhang, Zhiqiang; Gewurz, Benjamin E; Zhao, Bo; Zeng, Mu-Sheng.
Afiliação
  • Zhang H; Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology, South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Li Y; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Wang HB; Guangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Zhang A; Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology, South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Chen ML; Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology, South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Fang ZX; Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology, South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Dong XD; Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology, South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Li SB; Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology, South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Du Y; Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology, South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Xiong D; Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology, South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • He JY; Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology, South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Li MZ; Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology, South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Liu YM; Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology, South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Zhou AJ; Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology, South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Zhong Q; Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology, South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Zeng YX; Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology, South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Kieff E; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Zhang Z; Immunobiology and Transplant Science Center, Houston Methodist Research Institute, Houston, TX, USA.
  • Gewurz BE; Department of Surgery, Weill Cornell Medical College of Cornell University, New York, NY, USA.
  • Zhao B; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Zeng MS; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. bzhao@bwh.harvard.edu.
Nat Microbiol ; 3(9): 1075, 2018 Sep.
Article em En | MEDLINE | ID: mdl-29679064
ABSTRACT
In the version of this Letter originally published, the authors reported on the use of 2,5-dimethylpyrrolyl benzoic acid to block Ephrin receptors. In 2011, it was reported that newly synthesized 2,5-dimethylpyrrolyl benzoic acid lacked the previously reported EphA2 antagonizing activity1. However, the purchased compound did in fact have the activity initially reported, suggesting that an uncharacterized alteration occurred during storage. The authors therefore wish to clarify that the compound used in their study should be more accurately referred to as a 2,5-dimethylpyrrolyl benzoic acid derivative. All references to 2,5-dimethylpyrrolyl benzoic acid in the Letter have now been changed to reflect this.Although 2,5-dimethylpyrrolyl benzoic acid derivatives have been reported to have off-target effects2, as do most small-molecule inhibitors, the multiple complementary methods and techniques used demonstrate that EphA2 is a key Epstein-Barr virus epithelial cell receptor. The conclusions of the study are therefore unchanged.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Nat Microbiol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Nat Microbiol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: China